Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - Other
Status
Ended
Participants planned
16
Countries
1
Sites
1
Healthy volunteers
Key facts
- Sponsor
- Noucor Health S.A.
- Participant type
- Healthy volunteers
- Age range
- 18-64 years
- Gender
- Male and Female
- Therapeutic area
- Not possible to specify
- Trial duration
- 3 Sep 2025 → 6 Nov 2025
- Decision date (initial)
- 2025-08-20
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- No
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Healthy volunteers
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Noucor Health S.A.
- Sponsor organisation
- Noucor Health S.A.
- Address
- Avinguda Del Cami Reial 51-57
- City
- Palau-Solita I Plegamans
- Postcode
- 08184
- Country
- Spain
Scientific contact point
- Organisation
- Noucor Health S.A.
- Contact name
- Daniel Peris
Public contact point
- Organisation
- Noucor Health S.A.
- Contact name
- Daniel Peris
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Spain | Ended | 16 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Spain | 2025-09-03 | 2025-11-06 | 2025-09-08 | 2025-09-23 |
Application history
1 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2025-05-23 | Spain | Acceptable 2025-08-19
|
2025-08-20 |